Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.

ABSTRACT:

Objective

Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis. Fenofibrate may reduce HF events through multiple mechanisms. We sought to study the effect of fenofibrate (vs. placebo) in HF outcomes among patients with T2D receiving simvastatin enrolled in the Action to Control Cardiovascular Risk in Diabetes lipid trial (ACCORD Lipid).

Research design and methods

We used Cox regression analysis with background glucose-lowering strategy as the stratification variable. The median follow-up was 4.7 years.

Results

A total of 5,518 patients were included. Median age was 62 years, and 31% were women. Prior HF history was present in 5% of the patients. The composite outcome of HF hospitalization or

SUBMITTER: Ferreira JP 

PROVIDER: S-EPMC9274224 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature